NeuroDerm Presents Three Posters at the 20th International Congress of Parkinson’s Disease and Movement Disorders


(June 24, 2016) – NeuroDerm. a clinical-stage pharmaceutical company developing drugs for central nervous system diseases, presented pre-clinical data investigating ND0701, its new apomorphine product candidate for the treatment of Parkinson's disease, as well as the design of its ongoing Phase II clinical trial of ND0612H for the treatment of advanced Parkinson's diseases and additional clinical and pre-clinical data on the effect of continuous carbidopa administration on levodopa plasma levels.  The data were presented at the 20th International Congress of Parkinson's Disease and Movement Disorders taking place this month in Berlin. Read more…

Click for a printer friendly version

Back to top